wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q27908043-7345FA2C-B37A-445E-8CD7-16ADFDC14C47
Q27908043-7345FA2C-B37A-445E-8CD7-16ADFDC14C47
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27908043-7345FA2C-B37A-445E-8CD7-16ADFDC14C47
DNMT3A R882
P3355
Q27908043-7345FA2C-B37A-445E-8CD7-16ADFDC14C47
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27908043-7345FA2C-B37A-445E-8CD7-16ADFDC14C47
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0289fe90d783b2539e0990e79433ea67555606ca
P1310
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
P2175
acute myeloid leukemia
P4271
CIViC 4-star trust rating
P459
CIViC evidence level B
P3355
daunorubicin